XML 19 R5.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Total
Beginning balance at Dec. 31, 2019 $ 15 $ 270,492 $ (340,829) $ (70,322)
Beginning balance (in shares) at Dec. 31, 2019 [1] 14,838,213      
Issuance of common stock and warrants, net of issuance cost $ 18 41,325   41,343
Issuance of common stock and warrants, net of issuance cost (in shares) [1] 17,604,423      
Share-based compensation related to stock options   1,607   1,607
Share-based compensation related to restricted stock awards   505   505
Share-based compensation related to restricted stock awards (in shares) [1] 694,073      
Exercise of warrants   472   472
Exercise of warrants (in shares) [1] 200,000      
Net loss for the period     (6,920) (6,920)
Ending balance at Sep. 30, 2020 $ 33 314,401 (347,749) (33,315)
Ending balance (in shares) at Sep. 30, 2020 [1] 33,336,709      
Beginning balance at Jun. 30, 2020 $ 33 308,515 (343,312) (34,764)
Beginning balance (in shares) at Jun. 30, 2020 [1] 32,442,636      
Share-based compensation related to stock options   909   909
Share-based compensation related to restricted stock awards   505   505
Share-based compensation related to restricted stock awards (in shares) [1] 694,073      
Exercise of warrants   472   472
Exercise of warrants (in shares) [1] 200,000      
Note receivable payment   4,000   4,000
Net loss for the period     (4,437) (4,437)
Ending balance at Sep. 30, 2020 $ 33 314,401 (347,749) (33,315)
Ending balance (in shares) at Sep. 30, 2020 [1] 33,336,709      
Beginning balance at Dec. 31, 2020 $ 35 320,280 (347,352) (27,037)
Beginning balance (in shares) at Dec. 31, 2020 [1] 34,765,280      
Issuance of common stock, net of issuance cost $ 9 37,616   37,625
Issuance of common stock, net of issuance cost (in shares) [1] 8,749,999      
Issuance of common stock under the Sales Agreement, net $ 2 8,573   8,575
Issuance of common stock under the Sales Agreement, net (in shares) [1] 1,867,552      
Share-based compensation related to stock options   1,176   1,176
Share-based compensation related to restricted stock awards   781   781
Exercise of warrants (in shares) [1] 173,816      
Reacquisition of equity component of convertible notes   (12,019)   (12,019)
Equity component of convertible notes, net of transaction costs   (12,027)   (12,027)
Net loss for the period     (20,915) (20,915)
Ending balance at Sep. 30, 2021 $ 46 368,434 (368,267) 213
Ending balance (in shares) at Sep. 30, 2021 [1] 45,556,647      
Beginning balance at Jun. 30, 2021 $ 46 367,863 (364,068) 3,841
Beginning balance (in shares) at Jun. 30, 2021 [1] 45,556,647      
Share-based compensation related to stock options   344   344
Share-based compensation related to restricted stock awards   219   219
Reacquisition of equity component of convertible notes   (12,019)   (12,019)
Equity component of convertible notes, net of transaction costs   12,027   12,027
Net loss for the period     (4,199) (4,199)
Ending balance at Sep. 30, 2021 $ 46 $ 368,434 $ (368,267) $ 213
Ending balance (in shares) at Sep. 30, 2021 [1] 45,556,647      
[1] Common stock, $0.001 par value; Authorized – as of September 30, 2021 and 2020 - 120,000,000 shares.